InsiderTrades.com logo
The Gold Grab of the Century
From Colonial Metals   |   Ad
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.
Eric Drape net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Eric Drape Biography and Net Worth

VP of Teva Pharmaceutical Industries
Eric Drapé joined Teva in 2014 and became Executive Vice President and Chief Quality Officer of the Teva Group in 2015, leading operations for one of the largest manufacturing networks in the pharma industry.

The Teva Global Operations (TGO) team contributes to Teva’s performance by supporting the execution of new product launches while consistently driving cost savings and improvements in efficiencies, competitiveness and service across the global manufacturing network and supply chain.

Prior to this role, Eric Drapé served in various senior management positions, notably heading up Teva's Biologics Operations and as Senior Vice President of Technical Operations Steriles, Respiratory and Biologics.

Before joining Teva, he managed Technical Operations for Ipsen Pharma and served in several leading positions at Novo Nordisk.

Eric holds a Pharm.D and a DESS in Analytical Control of Drugs from the Université Paris XI. He also received his Executive MBA from the Scandinavian International Management Institute in Copenhagen.

What is Eric Drape's net worth?

The estimated net worth of Eric Drape is at least $128,538.25 as of February 28th, 2024. Mr. Drape owns 9,701 shares of Teva Pharmaceutical Industries stock worth more than $128,538 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Drape may own. Additionally, Mr. Drape receives a salary of $1,910,000.00 as VP at Teva Pharmaceutical Industries. Learn More about Eric Drape's net worth.

How old is Eric Drape?

Mr. Drape is currently 62 years old. There are 4 older executives and no younger executives at Teva Pharmaceutical Industries. Learn More on Eric Drape's age.

What is Eric Drape's salary?

As the VP of Teva Pharmaceutical Industries Limited, Mr. Drape earns $1,910,000.00 per year. There are 2 executives that earn more than Mr. Drape. The highest earning executive at Teva Pharmaceutical Industries is Mr. Eliyahu Sharon Kalif, Executive VP & CFO, who commands a salary of $2,010,000.00 per year. Learn More on Eric Drape's salary.

How do I contact Eric Drape?

The corporate mailing address for Mr. Drape and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Eric Drape's contact information.

Has Eric Drape been buying or selling shares of Teva Pharmaceutical Industries?

Eric Drape has not been actively trading shares of Teva Pharmaceutical Industries over the course of the past ninety days. Most recently, Eric Drape sold 9,815 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $13.12, for a transaction totalling $128,772.80. Following the completion of the sale, the vice president now directly owns 9,701 shares of the company's stock, valued at $127,277.12. Learn More on Eric Drape's trading history.

Who are Teva Pharmaceutical Industries' active insiders?

Teva Pharmaceutical Industries' insider roster includes Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.

Are insiders buying or selling shares of Teva Pharmaceutical Industries?

During the last twelve months, insiders at the sold shares 9 times. They sold a total of 480,586 shares worth more than $5,931,942.06. The most recent insider tranaction occured on March, 5th when EVP Mark Sabag sold 100,000 shares worth more than $1,352,000.00. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.

Information on this page was last updated on 3/5/2024.

Eric Drape Insider Trading History at Teva Pharmaceutical Industries

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2024Sell9,815$13.12$128,772.809,701View SEC Filing Icon  
2/16/2024Sell173,261$13.05$2,261,056.051View SEC Filing Icon  
5/21/2021Sell40,000$11.01$440,400.0033,128View SEC Filing Icon  
2/19/2020Sell8,000$12.51$100,080.0021,494View SEC Filing Icon  
See Full Table

Eric Drape Buying and Selling Activity at Teva Pharmaceutical Industries

This chart shows Eric Drape's buying and selling at Teva Pharmaceutical Industries by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Read More

Today's Range

Now: $13.25
Low: $12.80
High: $13.30

50 Day Range

MA: $13.50
Low: $12.78
High: $14.44

2 Week Range

Now: $13.25
Low: $7.09
High: $14.47

Volume

8,520,349 shs

Average Volume

8,417,266 shs

Market Capitalization

$14.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05
The Gold Grab of the Century
From Colonial Metals   |   Ad
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.